Support from Corporate Partners helps GI Cancer Trials unlock the answers to better treatments for the 37,567 Australians diagnosed with gastro-intestinal (GI) cancer each year. With 50 Australians losing their lives to the disease every day, the stakes are high.
We thank the following companies for their support.
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Taiho
Taiho Pharma Oceania is part of Taiho Pharmaceuticals group, a global, research-driven pharmaceutical company dedicated to delivering innovative therapies for patients with cancer.
Taiho’s robust global pipeline focuses on advancing treatments in oncology and haematology, particularly for patients with unmet medical needs. The company specializes in the development and commercialization of orally administered anti-cancer agents.
Driven by the corporate philosophy of “delivering new treatments, creating future smiles,” Taiho Pharma Oceania established its presence in Australia in 2024 with the aim of bringing novel therapies to local patients.